STEMON Co. Ltd

STEMON Inc. is a specialized cell reprogramming popularization-leading company, opening up a new future using this game changer’s technology. Our mission is to chase a new health for good health and to be a leader in autologous cell therapy with Entr-based automation system.

Stemon Inc. was established in March 2018, and based on our original technologies for cell reprogramming (Entr® technology) and mass production of exosome (Reprosome®) with selective specific factor (cell reprogramming factor) it has developed and produced extracellular vesicles-based therapeutics, medical devices, and dermal and hair care product.

Entr® (ultrasound-directed permeation of Environmental transition-guided cellular reprogramming), an original technology for cell reprogramming with only ultrasound and environmental factors without use of genes, unlike conventional methods. Stemon Inc. succeeded in mass production of Reprosome, various customized exosomes induced from dermal fibroblasts using the Entr® automation system, and is currently promoting the development of treatments for various intractable diseases, including immune and respiratory diseases. UltraRepro®, recently developed by Stemon Inc., is the world's first equipment for automating Entr® core technology, and suggesting alternatives to overcome a lot of problems such as the low efficiency, stability, and immune rejection of conventional cell therapies.

Our revenue generation strategy is to promote our dermal and hair care products to cosmetic surgery clinics and dermatologist, to expand overseas through various route, and also to license out with global companies. In a new era, Stemon Inc. will grow up into a GAME CHANGER company that prepares the future for human health and longevity to accelerate the popularization of autologous cell therapy in the future, ultimately realizing the happiness of all mankind.